← Back to Search

Diagnostic Tool

No trauma or PTSD for Post-Traumatic Stress Disorder

N/A
Waitlist Available
Led By Naser Ahmadi, MD
Research Sponsored by Senseye, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 9 weeks
Awards & highlights

Study Summary

This pilot study will investigate the feasibility, acceptability, repeatability, accuracy and efficacy of the Senseye OBCI diagnostic tool to assess the presence and severity of PTSD symptoms and monitor response to trauma-informed interventions. A total of 68 adults will be included in the study with a follow-up time point of 9 weeks post-initial intervention.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 9 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Agreement between Senseye OBCI measures and gold-standard measures
Feasibility of the Senseye tool
Test-retest for repeatability of the Senseye tool
Secondary outcome measures
Prognostic value by comparing Senseye OBCI to core PTSD symptoms

Trial Design

3Treatment groups
Experimental Treatment
Group I: Trauma+ & PTSDExperimental Treatment2 Interventions
Patients diagnosed with significant trauma exposure and PTSD
Group II: Trauma+ & No PTSDExperimental Treatment2 Interventions
Patients diagnosed with significant trauma exposure but no PTSD
Group III: No trauma or PTSDExperimental Treatment2 Interventions
Healthy adults without known major psychiatric disorders

Find a Location

Who is running the clinical trial?

Senseye, Inc.Lead Sponsor
1 Previous Clinical Trials
1,000 Total Patients Enrolled
Naser Ahmadi, MDPrincipal InvestigatorOlive View - UCLA

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~20 spots leftby May 2025